Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Abstract 1580: Investigating the tumor microenvironment of pancreatic ductal adenocarcinoma with BRCA2 mutation

View through CrossRef
Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and deadliest cancers with a survival rate of less than 12% at 5 years. It is estimated that around 14% of human PDAC contain mutations in genes involved in DNA Damage Repair (DDR), including BRCA1/2, ATM, and others. Additionally, PDAC has an extensive network of extracellular matrix components surrounding the tumor in the stroma, such as cancer-associated fibroblasts, which promote cancer cell growth. The interactions of the tumor with its tumor microenvironment and stroma can bring vulnerabilities that could be targeted if identified. New therapeutic strategies to those targets can be developed for specifically PDAC with DDR mutations. Using publicly available RNA-seq dataset of PDAC patients from The Cancer Genome Atlas (TCGA), I computationally estimated the infiltration of immune and stromal cell types into the tumor. From the analyses, I found that there was a significant difference in the migration of Common Lymphoid Progenitor (CLP) cells into PDAC with mutations to DDR genes. CLP cells usually divide into T-cells, B-cells, and NK cells, suggesting that DDR mutations could cause a more immunogenic environment. There was also a decrease in the infiltration of stromal elements, mainly fibroblasts, into PDAC with mutations to DDR genes. In the experiment I am currently working on, I hypothesize there are also in vivo differences in the infiltration rates of certain immune cell types and fibroblasts into BRCA2-mutated PDAC, since BRCA2 is the most commonly mutated DDR gene in PDAC. For my current experimental design, the mice in the experimental group will be orthotopically implanted with PDAC with Brca2 knockout. The control group will have mice orthotopically implanted with PDAC without Brca2 knockout. After letting the tumors grow for 3 weeks, the mice will be sacrificed and the pancreatic tumors will be collected and stained through trichrome staining. Trichrome staining probes for the stromal cancer-associated fibroblasts. Furthermore, immunohistochemistry (IHC) staining will be done to look for specific populations of cells, such as specific types of fibroblasts, effective and immunosuppressive immune cells including T-cells, B-cells, and NK cells. The aim is to see whether the computational findings in regards to the tumor microenvironment are also reflected in vivo. I will have the data from this experiment by the time of the conference in April 2024. Overall, my project is about investigating the tumor microenvironment and fibroblast abundance in PDAC with BRCA2 knockout mice, using computational data, IHC staining and trichrome staining. Citation Format: Fatimah Al-Musawi, Chang-il Hwang. Investigating the tumor microenvironment of pancreatic ductal adenocarcinoma with BRCA2 mutation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1580.
American Association for Cancer Research (AACR)
Title: Abstract 1580: Investigating the tumor microenvironment of pancreatic ductal adenocarcinoma with BRCA2 mutation
Description:
Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and deadliest cancers with a survival rate of less than 12% at 5 years.
It is estimated that around 14% of human PDAC contain mutations in genes involved in DNA Damage Repair (DDR), including BRCA1/2, ATM, and others.
Additionally, PDAC has an extensive network of extracellular matrix components surrounding the tumor in the stroma, such as cancer-associated fibroblasts, which promote cancer cell growth.
The interactions of the tumor with its tumor microenvironment and stroma can bring vulnerabilities that could be targeted if identified.
New therapeutic strategies to those targets can be developed for specifically PDAC with DDR mutations.
Using publicly available RNA-seq dataset of PDAC patients from The Cancer Genome Atlas (TCGA), I computationally estimated the infiltration of immune and stromal cell types into the tumor.
From the analyses, I found that there was a significant difference in the migration of Common Lymphoid Progenitor (CLP) cells into PDAC with mutations to DDR genes.
CLP cells usually divide into T-cells, B-cells, and NK cells, suggesting that DDR mutations could cause a more immunogenic environment.
There was also a decrease in the infiltration of stromal elements, mainly fibroblasts, into PDAC with mutations to DDR genes.
In the experiment I am currently working on, I hypothesize there are also in vivo differences in the infiltration rates of certain immune cell types and fibroblasts into BRCA2-mutated PDAC, since BRCA2 is the most commonly mutated DDR gene in PDAC.
For my current experimental design, the mice in the experimental group will be orthotopically implanted with PDAC with Brca2 knockout.
The control group will have mice orthotopically implanted with PDAC without Brca2 knockout.
After letting the tumors grow for 3 weeks, the mice will be sacrificed and the pancreatic tumors will be collected and stained through trichrome staining.
Trichrome staining probes for the stromal cancer-associated fibroblasts.
Furthermore, immunohistochemistry (IHC) staining will be done to look for specific populations of cells, such as specific types of fibroblasts, effective and immunosuppressive immune cells including T-cells, B-cells, and NK cells.
The aim is to see whether the computational findings in regards to the tumor microenvironment are also reflected in vivo.
I will have the data from this experiment by the time of the conference in April 2024.
Overall, my project is about investigating the tumor microenvironment and fibroblast abundance in PDAC with BRCA2 knockout mice, using computational data, IHC staining and trichrome staining.
Citation Format: Fatimah Al-Musawi, Chang-il Hwang.
Investigating the tumor microenvironment of pancreatic ductal adenocarcinoma with BRCA2 mutation [abstract].
In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA.
Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1580.

Related Results

Breast Cancer Susceptibility Gene 2 Deficiency Exacerbates Angiotensin‐II‐induced Endothelial Dysfunction and Apoptosis
Breast Cancer Susceptibility Gene 2 Deficiency Exacerbates Angiotensin‐II‐induced Endothelial Dysfunction and Apoptosis
BackgroundGerm‐line mutations in the tumour suppressor genes BRCA1 and BRCA2 (BReast CAncer susceptibility genes 1 & 2) predispose carriers to breast cancer. BRCA1 and BRCA2 he...
Abstract B013: A quest for deeper understanding of BRCA2 Variants of Uncertain Significance (VUS)
Abstract B013: A quest for deeper understanding of BRCA2 Variants of Uncertain Significance (VUS)
Abstract Deleterious mutations in homology-directed repair pathway genes impact both future cancer risk and therapeutic intervention options for cancer diagnosis and...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract Introduction Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Abstract 1779: BRCA2 interacts with an essential replication factor, MCM10.
Abstract 1779: BRCA2 interacts with an essential replication factor, MCM10.
Abstract The BRCA2 (Breast Cancer 2, early onset) gene is implicated in a variety of familial cancers. Loss of BRCA2 function results in severe defects in DNA double...
Abstract PO-041: Systemic screening of gene delivery methods in pancreatic ductal adenocarcinoma cells
Abstract PO-041: Systemic screening of gene delivery methods in pancreatic ductal adenocarcinoma cells
Abstract Deaths in the United States due to Pancreatic Ductal Adenocarcinoma (PDAC) has risen steadily since 1990, and PDAC is expected to be the second leading caus...
High KLK7 Expression Predicts Unfavorable Outcomes in Patients with Resectable Pancreatic Ductal Adenocarcinoma
High KLK7 Expression Predicts Unfavorable Outcomes in Patients with Resectable Pancreatic Ductal Adenocarcinoma
Abstract Background Studies have shown that kallikrein-related peptidase 7 (KLK7) is abnormally expressed in a various of tumours and plays a crucial role in tumour progres...
Abstract 1603: Intra-pancreatic fat promotes the progression of PDAC by activating thermogenesis
Abstract 1603: Intra-pancreatic fat promotes the progression of PDAC by activating thermogenesis
Abstract Background: The presence of minimal intra-pancreatic fat deposition (IPFD) in the healthy human pancreas has been demonstrated in numerous studies. But exce...

Back to Top